A new group of breast cancer patients with different survival outcomes can be differentiated immunohistochemically, although at times, this may remain without clinical impact if the patients are classified as HER2-0 or HER2-low-positive and the pathology is sufficiently accurate. Here, ERBB2 is linked to breast cancer.